Ellen O'Connor Vos Insider Trading $OPRX OptimizeRx Corp
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Ellen O'Connor Vos.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ellen O'Connor Vos. Ellen O'Connor Vos is Director in NTELOS HOLDINGS CORP. ($NTLS) and Director in OptimizeRx Corp ($OPRX).
Ellen O'Connor Vos in OptimizeRx Corp
Industry: SERVICES-BUSINESS SERVICES, NEC [7389]
Position of Ellen O'Connor Vos: Director
Holdings: 32,483 shares
Current Value: $24,037
Latest Transaction: Apr 02 2021
$OPRX Market Capitalization: $22.85M
$OPRX Previous Close: $0.74
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Ellen O'Connor Vos in OptimizeRx Corp
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 02 2021 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 539 | 0 | 32,483 | 31.9 K to 32.5 K (+1.69 %) |
| Apr 01 2020 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 8.75 | 1,000 | 8,750 | 28,022 | 27 K to 28 K (+3.70 %) |
| Mar 31 2020 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,784 | 0 | 27,022 | 24.2 K to 27 K (+11.49 %) |
| Jan 07 2020 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,084 | 0 | 24,238 | 22.2 K to 24.2 K (+9.41 %) |
| Nov 14 2019 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 9.62 | 600 | 5,772 | 22,154 | 21.6 K to 22.2 K (+2.78 %) |
| Oct 02 2019 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,084 | 0 | 21,554 | 19.5 K to 21.6 K (+10.70 %) |
| Mar 29 2019 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,084 | 0 | 17,386 | 15.3 K to 17.4 K (+13.62 %) |
| Oct 10 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.00 | 2,084 | 0 | 15,302 | 13.2 K to 15.3 K (+15.77 %) |
| Jul 03 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.00 | 2,084 | 0 | 13,218 | 11.1 K to 13.2 K (+18.72 %) |
| Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.72 | 250 | 2,680 | 11,134 | 10.9 K to 11.1 K (+2.30 %) |
| Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.47 | 1,100 | 11,517 | 10,884 | 9.8 K to 10.9 K (+11.24 %) |
| Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.29 | 50 | 515 | 9,784 | 9.7 K to 9.8 K (+0.51 %) |
| Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.35 | 400 | 4,140 | 9,734 | 9.3 K to 9.7 K (+4.29 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 1,000 | 750 | 28,000 | 27 K to 28 K (+3.70 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.74 | 2,000 | 1,480 | 27,000 | 25 K to 27 K (+8.00 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 25,000 | 24 K to 25 K (+4.17 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 24,000 | 23 K to 24 K (+4.35 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 2,000 | 1,620 | 23,000 | 21 K to 23 K (+9.52 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.80 | 1,000 | 800 | 21,000 | 20 K to 21 K (+5.00 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 20,000 | 19 K to 20 K (+5.26 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 19,000 | 18 K to 19 K (+5.56 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.82 | 2,000 | 1,640 | 18,000 | 16 K to 18 K (+12.50 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.85 | 1,000 | 850 | 16,000 | 15 K to 16 K (+6.67 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 2,000 | 1,620 | 15,000 | 13 K to 15 K (+15.38 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 13,000 | 12 K to 13 K (+8.33 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.85 | 1,000 | 850 | 12,000 | 11 K to 12 K (+9.09 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.70 | 1,000 | 700 | 11,000 | 10 K to 11 K (+10.00 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.71 | 1,000 | 710 | 10,000 | 9 K to 10 K (+11.11 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 1,000 | 750 | 9,000 | 8 K to 9 K (+12.50 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.77 | 1,000 | 770 | 8,000 | 7 K to 8 K (+14.29 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.70 | 2,000 | 1,400 | 7,000 | 5 K to 7 K (+40.00 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 2,000 | 1,500 | 5,000 | 3 K to 5 K (+66.67 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.73 | 1,000 | 730 | 3,000 | 2 K to 3 K (+50.00 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.76 | 1,000 | 760 | 2,000 | 1,000 to 2 K (+100.00 %) |
| May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.77 | 1,000 | 770 | 1,000 | 0 to 1,000 |
Page: 1